These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20815894)

  • 1. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.
    Zheng Y; Yu K; Du J; Jiang L; Zhang S; Han Y; Yu P; Tan Y
    J Exp Clin Cancer Res; 2010 Sep; 29(1):121. PubMed ID: 20815894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene.
    Yu K; Hu Y; Tan Y; Shen Z; Jiang S; Qian H; Liang B; Shan D
    Leuk Lymphoma; 2008 Jul; 49(7):1368-73. PubMed ID: 18452062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells.
    Hu WX; Chen HP; Yu K; Shen LX; Wang CY; Su SZ; Sui WJ; Shan DM; Li HZ
    Cancer Biother Radiopharm; 2012 Dec; 27(10):711-8. PubMed ID: 22988969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
    Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
    J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells.
    Jiang L; Yu K; DU J; Ni W; Han Y; Gao S; Li H; Wu J; Zheng Y; Tan Y
    Oncol Lett; 2011 Jul; 2(4):753-758. PubMed ID: 22848261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
    Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
    Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
    Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
    Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
    Chen F; Fan C; Gu X; Zhang H; Liu Q; Gao X; Lu J; He B; Lai X
    Med Sci Monit; 2015 Jul; 21():2110-5. PubMed ID: 26195067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
    Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
    J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.
    Hombach A; Schlimper C; Sievers E; Frank S; Schild HH; Sauerbruch T; Schmidt-Wolf IG; Abken H
    Gut; 2006 Aug; 55(8):1156-64. PubMed ID: 16188919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
    Lee SY; Olsen P; Lee DH; Kenoyer AL; Budde LE; O'Steen S; Green DJ; Heimfeld S; Jensen MC; Riddell SR; Press OW; Till BG
    J Immunother; 2018 Jan; 41(1):19-31. PubMed ID: 29176334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of anti-cD20scFv/CD80/CD28/zeta recombinant gene modified T cell and research on its targeting cytotoxicity].
    Hu YX; Yu K; Tan YX; Shen ZJ; Jiang SF; Qian HL; Hang B; Shan DM
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):111-4. PubMed ID: 17650672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
    Abbaszade Dibavar M; Soleimani M; Mohammadi MH; Zomorrod MS
    In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):321-332. PubMed ID: 38589736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
    Zhao Y; Wang QJ; Yang S; Kochenderfer JN; Zheng Z; Zhong X; Sadelain M; Eshhar Z; Rosenberg SA; Morgan RA
    J Immunol; 2009 Nov; 183(9):5563-74. PubMed ID: 19843940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
    Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
    J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
    Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
    Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression.
    Prado-Garcia H; Aguilar-Cazares D; Meneses-Flores M; Morales-Fuentes J; Lopez-Gonzalez JS
    Cancer Immunol Immunother; 2008 Mar; 57(3):325-36. PubMed ID: 17668204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise and potential pitfalls of chimeric antigen receptors.
    Sadelain M; Brentjens R; Rivière I
    Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.